A 68-year-old man with a history of benign prostatic hyperplasia and urinary retention presents to the emergency department with acute angle-closure glaucoma. His intraocular pressure (IOP) is 58 mmHg, and he has corneal edema and a mid-dilated pupil. The ophthalmologist prescribes pilocarpine drops immediately. Within 2 hours, his IOP drops to 32 mmHg. However, the patient develops severe bronchospasm, profuse salivation, and bradycardia (HR 42/min). Which of the following best explains the adverse effect profile observed in this patient?

Explanation

## Mechanism of Pilocarpine-Induced Adverse Effects ### Pilocarpine Pharmacology **Key Point:** Pilocarpine is a non-selective muscarinic agonist (M1, M2, M3, M4, M5) that mimics acetylcholine at all parasympathetic terminals. Unlike acetylcholine (which is rapidly hydrolyzed), pilocarpine has a longer half-life and penetrates the blood-brain barrier, allowing systemic effects. ### Mechanism of Toxicity | Muscarinic Receptor | Tissue Location | Effect of Activation | Clinical Manifestation | |---|---|---|---| | M2 | Cardiac SA/AV nodes | ↓ HR, ↓ AV conduction | Bradycardia | | M3 | Bronchial smooth muscle | Contraction | Bronchospasm | | M3 | Salivary glands | ↑ Secretion | Profuse salivation | | M3 | Ciliary muscle | Contraction | Miosis (therapeutic in glaucoma) | | M3 | Iris sphincter | Contraction | Miosis | **High-Yield:** The triad of **bronchospasm + bradycardia + salivation** is pathognomonic for non-selective muscarinic agonist toxicity. ### Why This Patient Is at Risk 1. **Age (68 years):** Older patients have reduced compensatory mechanisms for parasympathomimetic excess. 2. **Systemic absorption:** Topical ocular pilocarpine can be absorbed through nasolacrimal duct → nasopharynx → systemic circulation. 3. **No selective M1/M3 advantage:** Unlike selective agents (e.g., bethanechol, which is M3-preferring), pilocarpine activates M2 (cardiac) equally. **Clinical Pearl:** Pilocarpine toxicity is a classic exam scenario testing understanding of non-selective vs. selective muscarinic agonists. ### Management **Key Point:** Atropine (non-selective muscarinic antagonist) is the antidote. Dose: 0.5–1 mg IV, repeat every 5–10 min until signs of atropinization appear (dry mouth, tachycardia, dilated pupils). --- ## Why the Correct Answer is Correct Option 2 correctly identifies pilocarpine as a **non-selective muscarinic agonist** and links M2 activation (bradycardia) and M3 activation (bronchospasm, salivation) to the observed toxicity. This is the mechanism taught in all major pharmacology texts. --- ## Why Each Distractor Is Wrong | Option | Reason | |---|---| | 0 | **Partially true but incomplete.** Pilocarpine IS an M3 agonist, but the bradycardia (HR 42) is NOT explained by M3 alone — it requires M2 activation at the heart. The statement about COPD is speculative and not the primary mechanism. | | 1 | **Incorrect mechanism.** Pilocarpine is a direct muscarinic agonist, NOT an acetylcholinesterase inhibitor. Acetylcholinesterase inhibitors (e.g., physostigmine, neostigmine) cause similar symptoms but via a different mechanism (preventing ACh breakdown). | | 3 | **Completely false.** Pilocarpine does NOT inhibit monoamine oxidase. This is a distractor mixing unrelated pharmacology. MAO inhibitors cause hypertensive crises with foods containing tyramine, not the parasympathomimetic triad seen here. |